The FDA removed BPC-157 from Category 2 restrictions in April 2026 after related nominations were withdrawn, but this did not authorize compounding or place it on the positive 503A Bulk Drug Substances List. In July 2026, the Pharmacy Compounding Advisory Committee voted 8-6 (one abstention) to recommend adding the peptide to that list for compounding under Section 503A, despite FDA staff concerns over limited human safety and efficacy data. The non-binding recommendation begins a formal notice-and-comment rulemaking process that typically requires eight to twelve months or longer before any change takes effect. As of early September 2026, the FDA has not completed this step or announced placement on Category 1. Trader assessments center on the pace of agency review, potential influence from recent committee composition, and whether rulemaking advances before year-end deadlines.
Experimentelle KI-generierte Zusammenfassung mit Polymarket-Daten. Dies ist keine Handelsberatung und spielt keine Rolle bei der Auflösung dieses Marktes. · AktualisiertFDA verschiebt BPC-157 um… in Kategorie 1?
FDA verschiebt BPC-157 um… in Kategorie 1?
NEU
31. Dez. 2026
31. Dezember 2026
45%
$4,143 Vol.
31. Dezember 2026
$2,141 Vol.
45%
This market will resolve to “Yes” if the Food and Drug Administration (FDA) announces that it has reclassified or will reclassify BPC-157 to Category 1 of the Bulk Drug Substances List by the listed date, 11:59 PM ET. Otherwise, this market will resolve to “No”.
A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify.
Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date.
A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify.
The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.The FDA removed BPC-157 from Category 2 restrictions in April 2026 after related nominations were withdrawn, but this did not authorize compounding or place it on the positive 503A Bulk Drug Substances List. In July 2026, the Pharmacy Compounding Advisory Committee voted 8-6 (one abstention) to recommend adding the peptide to that list for compounding under Section 503A, despite FDA staff concerns over limited human safety and efficacy data. The non-binding recommendation begins a formal notice-and-comment rulemaking process that typically requires eight to twelve months or longer before any change takes effect. As of early September 2026, the FDA has not completed this step or announced placement on Category 1. Trader assessments center on the pace of agency review, potential influence from recent committee composition, and whether rulemaking advances before year-end deadlines.
This market will resolve to “Yes” if the Food and Drug Administration (FDA) announces that it has reclassified or will reclassify BPC-157 to Category 1 of the Bulk Drug Substances List by the listed date, 11:59 PM ET. Otherwise, this market will resolve to “No”.
A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify.
Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date.
A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify.
The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.
A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify.
Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date.
A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify.
The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.
Markt eröffnet: Jun 22, 2026, 10:10 PM ET
Volumen
$4,143Enddatum
1. Jan. 2027Markt eröffnet
Jun 22, 2026, 10:10 PM ETAbwickler
0x65070BE91...This market will resolve to “Yes” if the Food and Drug Administration (FDA) announces that it has reclassified or will reclassify BPC-157 to Category 1 of the Bulk Drug Substances List by the listed date, 11:59 PM ET. Otherwise, this market will resolve to “No”.
A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify.
Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date.
A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify.
The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.The FDA removed BPC-157 from Category 2 restrictions in April 2026 after related nominations were withdrawn, but this did not authorize compounding or place it on the positive 503A Bulk Drug Substances List. In July 2026, the Pharmacy Compounding Advisory Committee voted 8-6 (one abstention) to recommend adding the peptide to that list for compounding under Section 503A, despite FDA staff concerns over limited human safety and efficacy data. The non-binding recommendation begins a formal notice-and-comment rulemaking process that typically requires eight to twelve months or longer before any change takes effect. As of early September 2026, the FDA has not completed this step or announced placement on Category 1. Trader assessments center on the pace of agency review, potential influence from recent committee composition, and whether rulemaking advances before year-end deadlines.
This market will resolve to “Yes” if the Food and Drug Administration (FDA) announces that it has reclassified or will reclassify BPC-157 to Category 1 of the Bulk Drug Substances List by the listed date, 11:59 PM ET. Otherwise, this market will resolve to “No”.
A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify.
Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date.
A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify.
The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.
A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify.
Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date.
A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify.
The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.
Volumen
$4,143Enddatum
1. Jan. 2027Markt eröffnet
Jun 22, 2026, 10:10 PM ETAbwickler
0x65070BE91...The FDA removed BPC-157 from Category 2 restrictions in April 2026 after related nominations were withdrawn, but this did not authorize compounding or place it on the positive 503A Bulk Drug Substances List. In July 2026, the Pharmacy Compounding Advisory Committee voted 8-6 (one abstention) to recommend adding the peptide to that list for compounding under Section 503A, despite FDA staff concerns over limited human safety and efficacy data. The non-binding recommendation begins a formal notice-and-comment rulemaking process that typically requires eight to twelve months or longer before any change takes effect. As of early September 2026, the FDA has not completed this step or announced placement on Category 1. Trader assessments center on the pace of agency review, potential influence from recent committee composition, and whether rulemaking advances before year-end deadlines.
Experimentelle KI-generierte Zusammenfassung mit Polymarket-Daten. Dies ist keine Handelsberatung und spielt keine Rolle bei der Auflösung dieses Marktes. · Aktualisiert
Vorsicht bei externen Links.
Vorsicht bei externen Links.
Häufig gestellte Fragen